Brief: LogicBio Therapeutics Reports First Quarter 2022 Financial Results
16/05/2022 13:36
May 16 (Reuters) - LogicBio Therapeutics Inc LOGC.O :
* LOGICBIO THERAPEUTICS REPORTS FIRST QUARTER 2022 FINANCIAL
RESULTS AND HIGHLIGHTS RECENT BUSINESS UPDATES
* Q1 LOSS PER SHARE $0.20
* FDA LIFTED CLINICAL HOLD ON SUNRISE TRIAL IN PEDIATRIC
PATIENTS
WITH METHYLMALONIC ACIDEMIA
* QTRLY LOSS PER SHARE $0.20
* LOGICBIO THERAPEUTICS - BELIEVE CASH AND CASH EQUIVALENTS
AS OF
MARCH 31, 2022 WILL FUND OPERATING EXPENSES & CAPEX REQUIREMENTS
THROUGH Q1 OF 2023
Source text for Eikon: ID:nPnbF9c44a
Further company coverage: LOGC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on ContextLogic Holdings
See all newsContextLogic Holdings Q2 revenue flat as higher prices offset lower volumes
Brief: ContextLogic Holdings Q2 Adjusted EBITDA USD 10.8 Million
ContextLogic Holdings Q1 net income jumps on tax benefit
Brief: ContextLogic Holdings Q1 Net Income USD 17 Million
Brief: Contextlogic To Acquire US Salt From Emerald Lake In $907.5 Million Transaction, Creating New Business Ownership Platform In Partnership With Abrams Capital And BC Partners Credit